

# Wesley L Mckeithan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9294664/publications.pdf>

Version: 2024-02-01

18  
papers

1,059  
citations

840776

11  
h-index

888059

17  
g-index

18  
all docs

18  
docs citations

18  
times ranked

1768  
citing authors

#	ARTICLE	IF	CITATIONS
1	High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	297
2	Metabolic Maturation Media Improve Physiological Function of Human iPSC-Derived Cardiomyocytes. <i>Cell Reports</i> , 2020, 32, 107925.	6.4	198
3	Use of human induced pluripotent stem cell-derived cardiomyocytes to assess drug cardiotoxicity. <i>Nature Protocols</i> , 2018, 13, 3018-3041.	12.0	102
4	A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated Decay. <i>Circulation</i> , 2019, 139, 799-811.	1.6	91
5	Engineering synthetic morphogen systems that can program multicellular patterning. <i>Science</i> , 2020, 370, 327-331.	12.6	82
6	Id genes are essential for early heart formation. <i>Genes and Development</i> , 2017, 31, 1325-1338.	5.9	64
7	An Automated Platform for Assessment of Congenital and Drug-Induced Arrhythmia with hiPSC-Derived Cardiomyocytes. <i>Frontiers in Physiology</i> , 2017, 8, 766.	2.8	64
8	Whole-genome microRNA screening identifies <i>let-7</i> and <i>mir-18</i> as regulators of germ layer formation during early embryogenesis. <i>Genes and Development</i> , 2012, 26, 2567-2579.	5.9	59
9	Reengineering an Antiarrhythmic Drug Using Patient hiPSC Cardiomyocytes to Improve Therapeutic Potential and Reduce Toxicity. <i>Cell Stem Cell</i> , 2020, 27, 813-821.e6.	11.1	33
10	Will iPSC-cardiomyocytes revolutionize the discovery of drugs for heart disease?. <i>Current Opinion in Pharmacology</i> , 2018, 42, 55-61.	3.5	19
11	CRISPR/Cas9-based targeting of fluorescent reporters to human iPSCs to isolate atrial and ventricular-specific cardiomyocytes. <i>Scientific Reports</i> , 2021, 11, 3026.	3.3	18
12	Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 5384-5403.	6.4	8
13	Using iPSC Models to Probe Regulation of Cardiac Ion Channel Function. <i>Current Cardiology Reports</i> , 2018, 20, 57.	2.9	6
14	Small-molecule probe reveals a kinase cascade that links stress signaling to TCF/LEF and Wnt responsiveness. <i>Cell Chemical Biology</i> , 2021, 28, 625-635.e5.	5.2	5
15	Human iPSC-derived cardiomyocytes and pyridyl-phenyl mexiletine analogs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 46, 128162.	2.2	5
16	Serum-Free Generation of Multipotent Mesoderm (Kdr + ) Progenitor Cells in Mouse Embryonic Stem Cells for Functional Genomics Screening. <i>Current Protocols in Stem Cell Biology</i> , 2012, 23, Unit 1F.13.	3.0	5
17	Human-induced pluripotent stem cell-derived cardiomyocytes: Cardiovascular properties and metabolism and pharmacokinetics of deuterated mexiletine analogs. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00828.	2.4	3
18	Abstract 17056: High-Throughput Physiological Assay for Force and Stiffness Quantification in IPS Derived Cardiomyocytes. <i>Circulation</i> , 2018, 138, .	1.6	0